Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Vitaliani, Roberta (2009) PNS-EURONETWORK DATABASE: Encefaliti limbiche paraneoplastiche. [Tesi di dottorato]

Full text disponibile come:

Documento PDF

Abstract (inglese)

Background: Paraneoplastic limbic encephalitis (PLE) has been identified as a separated clinical entity by Corsellis et al. in 1965. It is clinically characterized by short term memory loss, psychiatric symptoms, confusion and seizures. To date there are only two case series with a limited number of patients describing PLE (Gultekin et al., 2000 and Lawn et al 2003).
Aims: This European multicenter study was designed to investigate the clinical, oncological and immunological profiles in a larger PLE population and to search for new antibodies targeted towards relevant neuronal antigens.
Methods: Patients. In 2002 a European network for Paraneoplastic neurological syndromes was developed (PNS-Euronetwork) thanks to the support of the European commission (QLGT-CT-2002-01756; LSSM-CT-2005 518174), which allowed the creation of a PNS database. The members of the network were invited to include in that database patients with PNS diagnosed after the year 2000. In this particular study we analyzed all PLE patients included in the database up till September 2008.
Antibodies detection. The patients’ sera were analyzed by immunohistochemistry on rat brain sections and western blot on brain protein homogenate or immunoblot with recombinant proteins. The presence of voltage gated potassium channel (VGKC) antibodies or voltage gated calcium channel (VGCC) antibodies was confirmed by radioimmunoprecipitation assay. Atypical reactivities were studied on hippocampal cells cultures and in particular cases immunocytochemistry on transfected HEK-293 cells was employed.
Statistical analysis. Proportional terms were used as descriptive statistics for categorical variables and median and mean for continue ones. A t-Student test was used to compare quantitative variables, whereas a Chi-square test or a Fisher exact test for qualitative ones. Survival curves were obtained using the Kaplan-Mayer method and the differences compared with the Log-rank test. The analysis were performed using SAS (version 9.02, SAS system, Cary NC)
Results: In the PNS-database 917 patients were included and 104 of these were affected by PLE. The latter group was made up of 66 males and 38 females, and their median age was 61.5 years. The clinical picture was characterized by short term memory loss (77%), confusional state (54.8%), seizures (44.2%) - mainly partial seizures (complex 37%, simple 32.6%)- and psychiatric disorders (52.8%) -mostly abnormal behavior (54.5%) and depression (32.7%). In 49 of our patients other symptoms were also detected: ataxia (n=15), neuropathy (n=11), brainstem encephalitis (n=9) and dysautonomia (n=8). These patients were referred as having PLE “plus”. A tumor was identified in 90.4% of patients: the more frequent ones were small cell lung cancer (SCLC) (39.4%) and testicular cancer (9.6%); worthy of note was the detection in two cases of a gastric cancer, which has never been reported in association with PLE. Anti-neuronal antibodies were present in 87.5% of patients and the most frequent ones were anti-Hu (56%) and anti-Ma2 (24.2%). Anti-Hu patients had more often SCLC (p<0.0001) and a worse response to tumor treatment (p=0.044) than patients with anti-Ma2 or patients without antibodies. On the other hand, other reactivities such as anti-VGKC (n=2), anti-N-metil-D-aspartate receptor (anti-NMDAR) (n=2) and anti-Tr (n=1) were rarely identified. Moreover in one patient we detected a new antibody directed against the gluR2 sub-unit of the AMPA (?-ammino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor. Only 12.5% of patients with PLE did not have anti-neuronal antibodies, compared to 40% of cases reported in literature.
The CSF showed inflammatory signs (increased cells and/or proteins content and/or positive presence of oligoclonal bands) in 58 out of 83 available exams. There was no difference among CSF results regardless of the timing of lumbar puncture (before or after 3 months from the clinical onset). The brain MRI was unremarkable in 26% of cases, but 11% of these had a positive FDG-PET brain scan. Forty-six patients received and immunomodulatory treatment (mainly steroids) and 16 improved by at least 1 point on the modified Rankin Scale. Instead, by treating the tumor, a significant improvement of the neurological syndrome was obtained in 23 out of 76 patients in whom the tumor was detected after the neurological onset. The different clinical, oncological and immunological characteristics of the patients with PLE “plus” and PLE “pure” were compared. We did not find significant differences between these two groups with the exception of the prevalence of testicular cancer in the “pure” PLE cohort. In the PLE “plus” group, 21 patients could be classified as having paraneoplastic encephalomyelitis (PEM). This subgroup was then compared with the PLE “plus” cohort (28 patients): PEM patients were older (p=0,0221), and were more frequently associated with SCLC (p=0.0111), anti-Hu antibodies (p=0.0024), pathological MRI (p=0.0272) and mortality for PNS (p= 0.0160).
Conclusion: To our knowledge, this represents the largest series on PLE patients ever reported. We found that PLE is more frequent in males and it could be associated with different tumours including gastric cancer: this association has never been reported before. Moreover we observed a lower percentage of patients without antibodies compared to the literature and detected a new antibody (anti-AMPAR) which widens the spectrum of PLE associated with anti-neuronal surface antigens. We also found no significance difference between PLE “pure” and PLE “plus”, except for a higher prevalence of testicular cancer in the former group. Finally, the PLE “plus” cohort differs from the PEM group for age, association with SCLC, anti-Hu antibodies and mortality due to PNS.

Abstract (italiano)

Background: L’encefalite limbica paraneoplastica (ELP) è stata identificata per la prima volta come entità clinica distinta da Corsellis et al., nel 1965 e si caratterizza sotto il profilo clinico per la presenza di deficit della memoria a breve termine, confusione, sintomi psichiatrici e crisi epilettiche. A oggi lo stato dell’arte relativo a tale patologia deriva principalmente dalla descrizione di due serie con un numero limitato di pazienti (Gultekin et al., nel 2000 e Lawn et al., nel 2003). Più recentemente le conoscenze sull’ELP si sono ampliate grazie all’identificazione di nuove reattività anticorpali e al riconoscimento di diversi quadri di presentazione clinica.
Scopo: Questo studio Europeo multicentrico è stato disegnato per analizzare le caratteristiche cliniche, oncologiche e immunologiche di un ampio gruppo di pazienti affetti da ELP e per identificare eventuali nuove reattività anticorpali dirette contro importanti antigeni neuronali.
Metodi: Pazienti. Nel 2002 è stato costituito un Network Europeo per le sindromi neurologiche paraneoplastiche (PNS-Euronetwork) supportato dalla Commissione Europea (QLGT-CT-2002-01756; LSSM-CT-2005 518174). È stato in seguito, costruito un database (PNS-database) in cui tutti i centri partecipanti dovevano inserire i pazienti con sindrome neureurologica paraneoplastica (SNP) diagnosticata dopo il 2000. Nel nostro studio, sono stati inclusi tutti i pazienti in cui fosse presente una diagnosi di ELP inclusi nel database fino al settembre 2008.
Analisi delle reattività anticorpali. I sieri dei pazienti sono stati analizzati mediante immunoistochimica su sezioni di encefalo di ratto, western blot su estratti proteici neuronali e immunoblot con proteina ricombinate. La presenza di anticorpi anti-canali per il potassio voltaggio dipendenti (VGKC) o per canali per il calcio voltaggio dipendenti (VGCC) è stata confermata mediante radioimmunoprecipitazione. Reatività anticorpali atipiche sono inoltre state studiate su colture di cellule ippocampali. In casi particolari è stata inoltre utilizzata immunocitochimica su cellule HEK-293 transfettate.
Analisi statistica. Termini proporzionali sono stati usati come statistica descrittiva per variabili categoriche e media e mediana per variabili continue. Per confrontare variabili qualitative sono stai utilizzati Test Chi quadro o test di Fisher. Mentre per variabili quantitative è stato utilizzato il test T-Student. Analisi sulla sopravvivenza sono state ottenute attraverso il metodo di Kaplan Mayer e le differenze confrontate attraverso il Log-rank test. Le analisi sono state eseguite mediante SAS (versione 9.02, SAS system, Cary NC)
Risultati: Nel PNS database sono stati inclusi 917 pazienti di cui 104 risultarono affetti da PLE. I pazienti erano 66 maschi e 38 femmine di età media pari a 59.5 anni. La sindrome clinica si caratterizzava per la presenza di: deficit della memoria a breve termine (77%), stato confusionale (54.8%), crisi epilettiche (44.2%) -soprattutto di tipo parziale complesso (37%) o focale motorio (32.6%)- e sintomi psichiatrici (52.8%) -principalmente alterazione della personalità (54.5%) e depressione (32.6%). In 49 pazienti sono stati definiti come affetti da ELP “plus” in quanto presentavano sintomi indicativi del coinvolgimento di aree extralimbiche quali per esempio: atassia (n=15), neuropatia (n=11), encefalite del tronco (n=9), disautonomia (n=8). Un tumore è stato riconosciuto nel 90.4% dei pazienti ed i più frequenti sono stati lo SCLC (39.4%) ed il tumore testicolare (9.6%). Tra gli altri tumori, degno di nota è stato il riconoscimento in due casi dell’associazione con un tumore gastrico. Anticorpi anti-neurone sono stati riconosciuti nel 87.5% dei pazienti quelli più frequentemente riscontrati erano gli anti-Hu (56%) ed anti Ma2 (24.2%). I pazienti con anticorpi anti-Hu avevano più spesso uno SCLC (p<0.0001) ed avevano una SNP che rispondeva meno al trattamento del tumore (p=0.044) dei pazienti con anticorpi anti-Ma2 o senza anticorpi. Mentre raramente sono state riconosciute altre reattività anticorpali come anti-VGKC (n=2), anti-NMDAR (recettore N-Metil-D-aspartato) (n=2) and anti-Tr (n=1). Inoltre in un caso è stata riconosciuta una nuova reattività anticorpale diretta contro la sub unità gluR2 del recettore per il glutammato di tipo AMPA (?-ammino-3-idrossi-5-metil-4-isossazolpropionico acido). Solo il 12.5% dei casi non aveva anticorpi anti-neurone a confronto del 40% riportato in letteratura. All’esame del liquor si sono riconosciuti segni d’infiammazione (aumento delle cellule e/o delle proteine e/o presenza di bande oligoclonali) in 58 su 83 esami disponibili. Non si sono inoltre riscontrate differenze significative quando sono stati confrontati gli esami liquorali eseguiti a più o meno di 3 mesi dall’esordio clinico. La RNM encefalica è risultata normale nel 26% dei casi. Nell’11% dei pazienti in cui la RNM era negativa è invece stata dimostrata la presenza di una positività alla FDG-PET encefalica. 46/104 pazienti sono stati trattati con farmaci immunomodulatori (soprattutto steroidi) e 16 hanno mostrato un miglioramento di almeno un punto alla scala di Rankin modificata. Mentre con il trattamento del tumore si è ottenuto un miglioramento della sindrome neurologica in 23 su 76 pazienti in cui la diagnosi di neoplasia era successiva all’esordio della sindrome neurologica. Dal confronto delle caratteristiche cliniche, oncologiche ed immunologiche dei pazienti con ELP pura e plus non sono emerse differenze statisticamente significative se non per una maggiore frequenza del tumore testicolare nel primo gruppo. Nel gruppo con ELP plus inoltre, abbiamo identificato 21 soggetti che potevano essere riclassificati come affetti da encefalomielite paraneoplastica (EMP). Questi pazienti sono stati confrontati con i rimanenti 28 affetti da ELP plus. Da quest’analisi è emerso che i pazienti con EMP erano più anziani (p=0.0221) ed avevano più comunemente SCLC (p=0.0111), anticorpi anti-Hu (p=0.0024), RNM patologica (p=0.0272) e mortalità dovuta alla SNP (p=0.0160).
Conclusioni: La nostra è la più ampia casistica mai riportata in letteratura. I pazienti con ELP erano prevalentemente maschi ed avevano associate varie tipologie di tumore tra cui quella con tumore gastrico non precedentemente segnalata. Abbiamo inoltre osservato che una minor percentuale di pazienti, rispetto a quanto riportato in letteratura, non avevano anticorpi anti-neurone ed abbiamo anche identificato un nuovo anticorpo (anti-AMPAR) che allarga lo spettro delle ELP associate ad anticorpi diretti contro antigenti di superficie. Non abbiamo trovato differenze significative tra i casi con ELP pura e quelli con ELP plus tranne che per la maggior frequenza di tumore testicolare nel primo gruppo. Infine abbiamo osservato che la popolazione con ELP “plus” differiva da quella con EMP per età, maggiore associazione con SCLC, anticorpi anti-Hu e mortalità per patologia neurologica.

Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Tavolato, Bruno
Dottorato (corsi e scuole):Ciclo 21 > Scuole per il 21simo ciclo > SCIENZE MEDICHE, CLINICHE E SPERIMENTALI > NEUROSCIENZE
Data di deposito della tesi:28 Gennaio 2009
Anno di Pubblicazione:2009
Parole chiave (italiano / inglese):encefaliti limbiche paraneoplastiche; anticorpi anti-neurone; sindromi neurologiche paraneoplastiche; database
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/26 Neurologia
Struttura di riferimento:Dipartimenti > Dipartimento di Neuroscienze
Codice ID:1565
Depositato il:28 Gen 2009
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

[1] Posner JB. Paraneoplastic syndromes. In Posner JB (Ed), Neurolgic Complication of Cancer. Philadelphia, PA: FA Davis Co; 1995 p-353-385. Cerca con Google

[2] Posner JB. Immunology of Paraneoplastic Syndromes. Overview. Ann N Y Acad Sci 2003; 998:178-186. Cerca con Google

[3] Henson RA, Hoffman HL and Urich H. Encephalomyelitis with carcinoma. Brain 1965; 88:449-464. Cerca con Google

[4] Greenfield JG. Subacute spinocerebellar degeneration occurring in ederly patients. Brain 1934; 57: 161-176. Cerca con Google

[5] Henson RA, Russel DS, Wilkinson M. Carcinomatous neuropathy and myopathy. A clinic pathological study. Brain 1954; 77: 82-121. Cerca con Google

[6] Henson RA and Urich H. Encephalomyelitis with carcinoma. In Henson RA and Urich H (Eds), Cancer and the Nervous System. Oxford, Blackwell; 1982 p-314-345. Cerca con Google

[7] Denny-Brown D. Primary sensory neuropathy with muscular changes associated with carcinoma. J Neurol Neurosurg Psichiatry 1948; 11:73-87 Cerca con Google

[8] Graus F, Elkon KB, Cordn-Cardo C, Posner JB. Sensory Neuronopathy and small cell lung cancer. Anti neuronal antibody that also reacts with the tumor. Am. J Med 1986; 80:45-52. Cerca con Google

[9] Dalmau J, Graus J, Rosenblum MK, Posner J. Anti-Hu associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical studi of 71 patients. Medicine 1992; 71:59-72. Cerca con Google

[10] Luchinetti CF, Kimmel DW, Vanda AL. Paraneoplastic and oncologic profiles od patients seropositive for Type 1 antineuronal nuclear autoantibodies. Neurology 1998; 50:652-657. Cerca con Google

[11] Graus F, Keime-Guibert F, Rene R, Benyahhia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic ancephalomyelitis: analysis of 200 patients. Brain 2001; 24:1138-1148. Cerca con Google

[12] Keime-Guibert F, Graus F, Fleury A, Renè R, Honnorat J, Bro?t P, Delattre JY. Treatment of paraneoplastic neurological syndrome with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of imunoglobulins, cyclophosphamide and methylprednisone. J Neurol Neurosurg Psychiatry 2000; 68: 479-482. Cerca con Google

[13] Dropcho EJ. Antiamphiphysin antibodies with small cell lung carcinoma and paraneoplastic encephalomielitis. Ann Neurol 1996; 39:659-667. Cerca con Google

[14] Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, Butler M, De Camilli P, Michale D. Amphiphisin antibodies are associated with various paraneoplastic neurological syndromes and tumours. Arch Neurol 1999; 56:172-177. Cerca con Google

[15] Lennon VA, Manley HA, Kim KK, Parisi J, Kilimann MW, Bennaroch Eduardo E. Amphyphysin autoantibodies: aparaneoplastic seriological marker of breast and lung cancer-related Encephalomyeloradiculoneuritides but not classical stiffman syndrome. Neurology 1997; 48 (suppl 2): A434. Cerca con Google

[16] Saiz A, Dalmau J, Butler MH, Chen Q, Delattre JY, De Camilli P, Graus F. Anti-amphiphisin I autoantibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1999; 66:214-217. Cerca con Google

[17] Pittock SJ, Luchinetti CF, Parisi JE, Benearroch EE, Mokri B, Stephan CL, Kim KK, Kilimann MW, Lennon VA. Amphiphisin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005; 58:96-107. Cerca con Google

[18] Antione J, Honnorat J, Koeing F, Aguera M, Berlin MF, Michel D. Posterior uveitis and paraneoplastic encephalomyelitis whit auto-antibodies reacting against cytoplasmic protein of brain and retina. J Neurol Sci 1993; 163: 159-162. Cerca con Google

[19] Vernino S, Tuite P, Adler CH, Meschia JF, Boeve BJ, Boasberg P, Parisi JE, Lennon V. Paraneoplastic corea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol 2002; 51:625-630. Cerca con Google

[20] Yu Z, Kryzer TJ, Griesmann GE, Kim K, Bennaroch EE, Lennon VA. CRMP-5 Neuronal antibodies: marker of lung cancer and thymoma related autoimmunity. Ann Neurol 2001; 49:146-154. Cerca con Google

[21] Honnorat J, Cartalat-Cartel S, Ricard D, Camdessanchè JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC. Onco-neural antibodies and tumor type determine survival and neurologica symptoms in paraneoplastic neurologica syndromes with anti-Hu or CV2/CRMP5 J Neurol Neurosurg Psychiatry 2008; Cerca con Google

[22] Vernino S, Lenno VA. New Purkinje Cell Antibody (PCA-2): Marker of Lung Cancer-Related Neurological Autoimmunity. Ann. Neurol. 2000; 47: 297-305. Cerca con Google

[23] Chan KH, Vernino S, Lennon V. ANNA-3 Anti-Neuronal Neuronal Antibody: marker of Lung Cancer-Related Autoimmunity. Ann Neurol 2001; 50: 301-311. Cerca con Google

[24] Brierley JB, Corsellys JAN, Hierons R, Nevin S. Subacute encephalitis of later adult life mainly affecting the limbic areas. Brain 1960; 83:357-368. Cerca con Google

[25] Verhaart WJC. Gray matter degeneration of the CNS in carcinoma. Acta Neuropathol (Berl) 1961; 1:107-112. Cerca con Google

[26] Störring G, Hauss K, Ule G. Zur topischen Diagnostik des anamnestischen Symptomenkomplesxes. Psychiatr Neurol (Basel) 1962; 143:161-177. Cerca con Google

[27] Yahr MD, Duvosin RC, Cowen D. Encephalopathy associated with carcinoma. Trans Am Neurol Assoc 1965; 90:80-86. Cerca con Google

[28] Ulrich J, Spiess H, Huber R. Neurological synderomes as a remote effect of a malignant tumor (Ammon’s horn sclerosis in bronchial carcinoma). Schweiz Arch Neurol Neurochir Psychiatrye 1967;99:83-100. Cerca con Google

[29] Corsellis JAN, Goldberg GJ, Norton AR. Limbic encephalitis and its association with carcinoma”. Brain 1968; 91: 481-496. Cerca con Google

[30] Koeler J, Hufschmidt A, Hermele L, Volk B, Luking CH. Limbic encephalitis: two cases. J Neuroimmunol 1988;10:177-178. Cerca con Google

[31] Sutton RC, Lipper MH, Brashear HR. Limbic encephalitis occurring in association with Alzehimer’s disease. J Neurol Neurosurg Psychiatry 1993; 56:808-811. Cerca con Google

[32] Dirr LY, Elster AD, Donofrio PD, Smith M. Evolution of brain MRI abnormalities in limbic encephalitis. Neurology 1990; 40:1304-1306. Cerca con Google

[33] Scheid R, Lincke T, Voltz R, von Cramond DY, Sabri O. Serial 18F-fluoro-2 deoxy-D-Glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol 2004; 61:1785-1789. Cerca con Google

[34] Ances B, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Hougton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J. Neuropil Antibodies in treatment responsive limbic encephalitis: clinical, MRI and PFT correlates. Brain 2005; 128: 1764-1777. Cerca con Google

[35] Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings, and tumor association in 50 patients. Brain 2000; 123:1481-1494. Cerca con Google

[36] Tu?zu?n E, Dalmau J. Limbic encephalitis and variants: classification, diagnosis and treatment. The Neurologist 2007; 5:261-271. Cerca con Google

[37] Dorresteijn LD, Kappaelle AC, Reiner WO, Gijtenbek JM. Anti-amphiphysin associated limbic encephalitis: a paraneoplastic presentation of small cell carcinoma. J Neurol 2002; 249: 1307-1308. Cerca con Google

[38] Harloff A, Hummel S, Kleinschmidt E, Rauer S. Anti-Ri antibodies and limbic encepahlitis in a patient with carcinoid tumor of the lung. J Neurol 2005; 252:1404-1405. Cerca con Google

[39] Launay M, Bozzolo E, Venissac N, Delmont E, Freinrich A, Tomas P. Paraneoplastic limbic encefalitis with positive anti-Ri antibodies and mediastinal seminoma. Rev Neurol (Paris) 2008; 164:612-619. Cerca con Google

[40] Vernino S, Lennon VA. Autoantibody profiles and neurologica correlations of thimoma. Clin Cancer Res 2004; 10: 7270-7275. Cerca con Google

[41] Saiz A, Blanco Y, Sabater L, González F, Battaler L, Casamitjana R, Ramió-Torrentà L, Graus F. Specrtum of neurological syindromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563. Cerca con Google

[42] Sabater L, Gòmez-Choco, Saiz A, Graus F. BRserine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis. J Neuroimunol 2005; 170:186-190. Cerca con Google

[43] Fadul CE, Stommel EW, Dragnev KH, Dalmau JO. Focal paraneoplastic limbic encephalitis presenting as orgasmic epilepsy. J Neuro-Oncol 2005; 72:195-198. Cerca con Google

[44] Voltz R, Gultekin SH,Rosenfeld MR, Gerstner E, Eichen J, Posner JB, DalmauJ. A sierologic marker of paraneoplastic limbic and brainstem encephalitis in patients with testicular cancer. N Engl J Med 1999; 340(23):1773-1848. Cerca con Google

[45] Rosenfeld MR, Eichen J, Wade DF, Posner JP, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001; 50: 339-348. Cerca con Google

[46] Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR. Clinical analysis of anti-Ma2 associated encephalitis. Brain 2004; 127(8): 1831-1844. Cerca con Google

[47] Compta Y, Iranzo A, Santamaria J, Casamitjana R, Graus F. REM sleep behavior disorders and narcoleptic features in anti-Ma2 associated encephalitis. Sleep 2007; 30: 767-779. Cerca con Google

[48] Hoffmann LA, Jarius S, Pellkofer HL, Schuller M, Krumbholz M, Koenig F, Johannis W, la Fougere C, Vincent A, Voltz R. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008; 79: 767-773. Cerca con Google

[49] Mathew RM, Vanderberghe R, Garcia-Merino A, Yamamoto T, Landolfi JC, Rosenfeld MR, Rossi JE, Thiessen B, Dropcho EJ, Dalmau J. Orchiectomy for susrected microscopic tumor in patients with anti-Ma2 associated encephalitis. Neurology 2007; 68:900-905. Cerca con Google

[50] Kinirons P, Fulton A, Keohan M, Brennan P, Farrel MA, Moroney JT. Paraneoplastic limbic encephalitis and chorea associated with CRMP-5 neuronal antibodies. Neurology 2003; 61: 1623-1624. Cerca con Google

[51] Kellinghaus C, Kraus J, Blaes F, Nabavi DG, Schabitz WR. CRMP-5 autoantibodies in testicular cancer associated with limbic encephalitis and choreiform dyskinesia. Eur Neurol 2007; 57:241-243. Cerca con Google

[52] Knudsen A, Bredolt A, Storstein A, Oteldal L, Dvanger S, Krossness B., Honnorat J, Vedeler CA. Anibodies to CRMP3-4 associated with limbic encephalitis and thimoma. Clinical and Experimental Immunol 2007; 147: 16-22. Cerca con Google

[53] Graus F, Saiz A, Lai M, Bruna J, LóPFz F, Sabater L, Blanco Y, Rey MJ, Ribalta T, Dalmau J. Neuronal surface antigen antibodies in limbic encephalitis. Clinical immunological associations. Neurology 2008; 71: 930-936. Cerca con Google

[54] Hart IK. Aquired neuromiotonia: a new autoantibody-mediated neuronal potassium channelopathy. Am J Med Sci 2000; 319:209-216. Cerca con Google

[55] Morvan A. De la chorèe fibrillaire. Gazzette Hebdomadaire de Medicine et de Chirurgie. 1890; 27: 173-200. Cerca con Google

[56] Loscher WN, Wanschitz J, Reiners K, Quasthoff S. Morvan’s syndrome: clinical, laboratory, and in vitro electrophysiological studes. Muscle Nerve 2004; 30: 157-163. Cerca con Google

[57] Lee Ek, Maselli RA, Ellis WG, Agius MA. Morvan’s fibrillary chorea: a paraneoplastic manifestation of thymoma. J Neurol Neurosurg Psychiatry 1998; 65: 857-862. Cerca con Google

[58] Barber PA, Anderson NE, Vincent A. Morvan’s syndrome associated with voltage –gated K+ canne antibodies. Neurology 2000; 54: 771-772. Cerca con Google

[59] Liguori R, Vincent A, Clover L, Avoni P, Plazzi G, Cortelli P, Baruzzi A, Carey T, Gambetti P, Lugaresi E, Montagna P. Morvan’s syndrome: Peripheral and central nervous system and cardiac involvement with antibodies to voltage gated potassium channels. Brain 2001; 124:2417-2426. Cerca con Google

[60] Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Deter N, Clover L, Parkinson A, Bien CG, Omer S, Bethan L, Rossor MN, Palace J. Potassium channel antibody associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127:701-712. Cerca con Google

[61] Sekiguchi Y, Takahashi H, Masahiro M, Ito S, Shimada H, Hattori T, Kuwabara S. Potassium channel antibody associated encephalitis with hypothalamic lesion and intestinal pseudo-obstruction. J Neurol Sci 2007; 269: 176-179. Cerca con Google

[62] Jacob S, Irani SR, Rajabally Y, Grubneac A, Walters RJ, Yazaki M, Clover L, Vincent A. Hypotermia in VGKC antibody associated-limbic encephalitis. J Neurol Neurosurg Psychiatry 2008; 79:202-204. Cerca con Google

[63] Jarius S,Hoffma L, Clover L, Vincent A, Voltz R. CSF findings in patients with voltage gated potassium channel antibodies associated encephalitis. J Neurol Sci 2007; 268: 74-77. Cerca con Google

[64] Bukley C, Oger J, Clover L, Tu?zu?n E, Carpenter K, Psych D, Jackson M, Vincent A. Potassium Channel antibodies in two patients with reversible limbic Encephalitis. Ann Neurol 2001; 50: 73-78. Cerca con Google

[65] Pozo-Rosich P, Clover L, Saiz A, Vincent A, Graus F. Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol 2003; 54:530-533. Cerca con Google

[66]Thieben MJ, Lennon A, Boeve BF, Aksamit AJ, Keegan M, Verninno M. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibodies. Neurology 2004: 62: 1177-1182. Cerca con Google

[67] Ohshita T, Kawakami H, Maruyama H, Kohriyama T, Arimura K, Matsumoto M. Voltage gated potassium channel antibodies associated limbic encephalitis in a patient with thimoma. J Neurl Sci 2006; 250: 167-169. Cerca con Google

[68] Jarius S, Hoffman LA, Stich O, Clover L, Rauer S, Vincent A, Voltz R. Relative frequence of VGKC and classical paraneoplastic antibodies in patients with limbic encephalitis. J Neurol 2008; 225: 1100-1101. Cerca con Google

[69] Zuliani L, Tavolato B, Giometto B, Vincent A, Graus F. Paraneoplastic limbic encephalitis associated with potassium channel antibodies: value of anti-glial nuclear antibodies in indentifying the tumor. J Neurol Neurosurg Psychiatry 2007; 78:381-385. Cerca con Google

[70] Takamori M. Lambert-Eaton Myastenic Syndrome as an autoimmune chalcium channelopathy. Biochem Biophy Research Communications 2004; 322: 1347-1351. Cerca con Google

[71] Mason WP, Graus F, Lang B, Honnorat J, Delattre J-Y, Vallderiola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J. Small cell lung cancer, paraneoplastic cerebellar degeneration, and the Lamber-Eaton myasthenic syndrome Brain 1997; 120: 1279-1300. Cerca con Google

[72] Lawn ND, Westmoreland BF, Kiely MJ, Lennon V, Vernino S. Clinical, magnetic resonance imaging and elettroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003; 78: 1363-1368. Cerca con Google

[73] Weimer T, Boling W, Pryputniewicz D, Palade A. Temporal lobectomy for refractory status epilepticus in a case of limbic encephalitis. J Neurosurg 2008; 109: 742-745. Cerca con Google

[74] Vitaliani R, Maron W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms and hypoventilation in ovarian teratoma. Ann Neurol 2005; 58:594-604. Cerca con Google

[75] Yang YW, Tsai CH, Chang FC, Lu MK, Chiu PY. Reversible paraneoplastic limbic encephalitis caused by a benign ovarian teratoma: report of a case and review of the literature. J Neurooncol 2006; 80: 309-312. Cerca con Google

[76] Koide R, Shimizu T, Koike K, Dalmau J. EFA6 like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma. J Neurooncol 2007; 81:71-74. Cerca con Google

[77] Dalmau J, Tu?zu?n E, Wu H, Masjuan J, Rossi JE, Vloscin A, Baehring JM, Koide R, King D, Mason W , Sansing LH, Dicter MA, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-Methyl-D aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61: 25-36. Cerca con Google

[78] Shimazaki H, Ando Y, Nakano I, Dalmau J. Reversible limbic encephalitis with antibodies against the membrane of neurons of the hippocampus. J Neurol Neurosurg Psychiatry 2007: 78: 324-325. Cerca con Google

[79] Sansing LH, Tu?zu?n E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007; 3:291-296. Cerca con Google

[80] Izuka T, Sakai F, Ide T, Monzen T, Yoshi S, Iigaya M, Suzuki N, Hata T, Dalmau J. Anti-NMDA receptor encephalitis in Japan. Neurology 2008; 70: 504-511. Cerca con Google

[81] Novillo-Lòpez ME, Rossi JE, Dalmau J, Masjuan J. Treatment-responsive subacute limbic encephalitis and NMDA receptor antibodies in a man. Neurology 2008; 70: 728-729. Cerca con Google

[82] Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurons in sensory carcinomatous neuropathy. Brain 1965; 88:529-538. Cerca con Google

[83] Graus F, Damau J, Rene R, Tarà M, Verschuuren JJ, Cardenal F, Vinolas N, Garcia del Muro J, Vadell C, Mason Wp, Rosel R, Posner JB, Real FX. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Onc (1997) 15(8): 2866-2872. Cerca con Google

[84] Szabo A, Dalmau J, Manley G, Reosenfeld M, Wong E, Posner JB, Furneaux HM. HuD, a paraneoplastic encephalomyelitis antigen, conteins RNA binding domains and is homologus to Elav and Sex-lethal. Cell 1991; 67: 325-333. Cerca con Google

[85] Chung S, Jiang L, Chang S, Furneaux H. Purification and proprieties of HuD, a neuronal RNA binding protein. J Biol Chem 1996; 271:11518-11524. Cerca con Google

[86] Marusisch MF, Furneaux HM, Henion P, Weston JA. Hu neuronal proteins are expressed in proliferation neurogenic cells. J Neurobiol. 1994; 25:143-155. Cerca con Google

[87] Barami K, Iversen K, Forneaux H, Glodman SA. Hu proteins as an early marker of neuronal phenotipic differentiation by subependimal zone cells of the adult songbird forebrain. J Neurobiol. 1995; 28:82-101. Cerca con Google

[88] Manley GT, Sillevis Smitt PAE, Dalmau J,Posner JB. Hu antigens: reactivity with anti-Hu antibodies, tumor expression and major immunogenic sites. Ann Neurol. 1995; 38:102-110. Cerca con Google

[89] Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol 1983; 14:609-613. Cerca con Google

[90] Jeakle KA, Graus F, Hougton A, Cardoncardo C, Nielsen SL,Posner JB. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a purkinie cell cytoplasmatic protein antigen. Ann. Neurol. 1985; 18: 592-600. Cerca con Google

[91] Peterson K, Rosemblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degenerstion. A clinical analisis of 55 anti-Yo antibodies positive patients. Neurology 1992; 42:1931-1937. Cerca con Google

[92] Dropcho EJ, Chen YT, Posner JB, Old LJ. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci. 1987; 84: 4552-4556. Cerca con Google

[93] Fathallah-Shaykh H, Wolf S, Wong E, Posner JB, Furneaux HM.. Cloning of a leucine–zipPer protein recognized by the sera of patients with antibodies associated paraneoplastic cerebellar degeneration. Proc.Natl. Acad. Sci. 1991; 88:3451-3454. Cerca con Google

[94] OkanoHJ, Park WY, Corradi JP, Darnell RB. The cytoplasmic purkinje onconeuronal antigen cdr2 down regulates cMyc Function: implication for neuronal and tumor cell survival. Genes Dev. 1999; 16: 2087-2097. Cerca con Google

[95] Sakai K, Ogasawara T, Hirose G, Jaeckele KA, Greenlee JE. Analysis of autoantibody binding to 52 kD paraneoplastic cerebellar degeneration associated antigen expressed in recombinant protein. Ann. Neurol. 1993; 33:373-380. Cerca con Google

[96] Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post transcriptional Regulatory Mechanism Restricts expression of the Paraneoplastic cerebellar degeneration antigen cdr2 to Immune privileged Tissues. J. Neurosci. 1997; 17(4):1406-1415. Cerca con Google

[97] Albert ML, Austin ML, Darnell RB. detection and treatment of activated T cells in the cerebro spinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47:9-17. Cerca con Google

[98] Budde-Steffen C, Anderson NE, Rosemblum MK. Graus F, Ford D, Synek BJ, Wray SH, Posner, An antineuronal antibody in paraneoplastic opsoclonus Ann Neurol. 1988 May;23(5):528-531. Cerca con Google

[99] Luque FA, Furneaux HM, Ferziger Rrosemblum MK, Wray SH, Schold SC, Glantz MJ, Jaeckle Ka, Biran H, LesserM. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann. Neurol. 1991; 29: 241-251. Cerca con Google

[100] Pittock SJ, Luchinetti CF, Lennon VA. Antineuronal antibody type-2: Paraneoplastic accompainiments. Ann. Neurol. 2003;53:580-587. Cerca con Google

[101] Buckanovich RJ, Posner JB, Darnell RB. Nova, the paraneoplastic Ri antigen, is homologus to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 1993; 11:657-672. Cerca con Google

[102] Yang YYL, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as autoantigen target in POMA patients with dementia. Proc. Nat. Acad. Sci 1998; 95:13254-13459. Cerca con Google

[103] Solimena M, Folli F, Denis-Dononi S, Comi GC, Pozza G, DeCamilli P, Vicari AM. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man sindrome, epilepsy and type I diabetes mellitus. N. Engl. J. Med. 1988; 318:1012-1020. Cerca con Google

[104] Meinck HM, Faber L, Morgenthaler N, Seissler J, Maile S, Butler M, Solimena M, DeCamilli P, Scherbaum Antibodies against glutamic acid decarboxylase: Prevalence in neurological disease. J Neurol Neurosurg Psychiatry 2001; 71:100-103. Cerca con Google

[105] Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, De Andres C, Mastre J, Fabien N, Vighetto A, Casamitjana R, Thivolet C, Tavolato B, Antoine J, Truillas P, Graus F. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies:study of 14 patients. Arch Neurol 2001; 58:225-230. Cerca con Google

[106] Nemni R, Braghi S, Natali-Sora MG, Lampasona V, Bonifacio E, Comi G , Canal M. Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol 1994; 36:665-667. Cerca con Google

[107] Walikonis JE, Lennon VA. Radioimmunoassey for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid in stiff man syndrome and correlate of susceptibility to Type 1 diabetes mellitus. Mayo Clin Proc 1998; 73:1161-1166. Cerca con Google

[108] Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, Bates D, Cartlidge N, Bottazzo GF, Piccolo G, DeCamilli P. Autoantibodies to a 128-kd protein in three women with the stiff-an syndrome and breast cancer. N. Engl. J. Med. 1993; 328:564-551. Cerca con Google

[109] De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, Menick HM, Austoni M, Fassetta G, Bottazzo GF, Bates D, Cartlidge N, Solimena M, Kilimann MW. The synaptic vescicle- associated protein amphiphysin is the 128 kD autoantigen of the Stiff-Man syndrome with breast cancer. J. Exp. Med. 1993; 178:2219-2223. Cerca con Google

[110] Rogemond V, Honnorat J. Anti-CV2 Antibodies and Paraneoplastic Neurological Syndrome. Clin. Rev. Allergy Immunol. 2000; 19(1):51-59. Cerca con Google

[111] Honnorat J, ByK T, Kuster I, Aguera M,Richard D, Rogemond V,Quac T, Aunis D, Sobel A. Mattei MG, Kolattukudy P, Berlin MF, Antoine JC. Ulip/CRMP5 proteins are recognized by autoantibody in paraneoplastic neurological syndromes. Eur. J. Neurosci. 1999; 11:4226-4232. Cerca con Google

[112] Richard D, Rogemond V, Charrier E, Aguera M, Bagnard D, Belin MF, Thomasset N, Honnorat J. Isolation and expression pattern of human Unc-33-like phosphoprotein6/collapsine respone mediator protein 5 (Ulip6/ CRMP5): coexistence with Ulip2/CRMP2 in Sema3A-sensitive oligodendrocytes. J. Neurosci. 2001; 21:7203-7214. Cerca con Google

[113] Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R, arinC, Vecht CHJ, Arbizu T, Targa C, Moll JW. Immunological Charactherization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodking’s disease. J Neuroimmunol. 1997; 74:55-61. Cerca con Google

[114] Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, Batcelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld M. Ma1, a novel neuron-testis specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122:27-39. Cerca con Google

[115] Battaler L, Wade DF, Fuller GN, Rosenfeld MR, Dalmau J. Cerebellar degeneration and autoimmunity to zinc-finger proteins of the cerebellum. Neurology 2002; 59:1985-1987. Cerca con Google

[116] Battaler L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small cell lung cancer. Neurology 2004; 62:778-782. Cerca con Google

[117] Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, Dalmau J. Anti-glial nuclear antibody marker of lung cancer-related paraneoplastic neurologica syndromes. J Neuroimmunol 2005; 165:166-171. Cerca con Google

[118] Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F, Sox1 antibodies are a markers of paraneoplastic Lambert-Eaton Myastenic Syndrome. Neurology 2008;70:940-928. Cerca con Google

[119] Lizcano JM, Go?rasson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawlwy SA, Udd L, Ma?kela TP, Hardie DG, Alessi DR. LKB1 is a master kinase that activates 13 kinase of the AMPK subfamily, including MARK/PAR-1. EMBO J 2004; 23: 833-843. Cerca con Google

[120] Kishi M, pan YA, Crump JG, Sanes JR. Mammalian SAD Kinase are required for neuronal polarization. Scince 2005; 307: 929-932. Cerca con Google

[121] Carpentier AF, Delattre JY. The Lambert-Eaton Myasthenic Syndrome. Clin. Rev. All. Immunol.2001; 20: 155-158. Cerca con Google

[122] Hart IK, Waters C, Vincent A, Nevland C, Besson D, Pongs O, Morris C, Newsom- Devis J. Autoantibodies detected to expressed K+ Channel are implicated in neuromyotonia. Ann Neurol 1997; 41: 238-246. Cerca con Google

[123] Keopa KA, Elman LB, Lang B, Vincent A, Scherer SS. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channel: subunit specifity correlates with clinical manifestations. Brain 2006:129:1570-1584. Cerca con Google

[124] Sillevis Smitt P, Kinoschita A, De Leeuw B, Moll W, Cosemans M, Jaarsma D, Henzen-Logmans S, Vecht C, De Zeeuw C, Sekiyama N, Nakanishi S, Shigemoto R. Paraneoplastic Cerebellar Ataxia Due to Autoantibodies Against A Glutamate Receptor. N.Engl. J.Med. 2000; 342(1):21-27. Cerca con Google

[125] DeGiorgio LA, Kostanitinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A substet of lupus dsDNA antibodies cross react with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med 2001; 7:1189-1193. Cerca con Google

[126] Takahashi Y, Mori H, Mishina M, Watanabe M, FuJiWara T, Shimomura J, Aiba H, Miyajima T, Saito Y, Nezu A, Nischida H, Imai K, Sakaguchi N, Kondo N. Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 2003;61: 891-896. Cerca con Google

[Kimura A, Sakurai T, Suzuki Y, Hayashi Y, Huzomi I, Watanabe O, Arimura K, Takahashi Y, Inuzuka T. Autoantibodies against glutamate receptor ?2- subunity detected in a subgroup of patients with reversible autoimmune limbic encephalitis. Eur Neurol 2007; 58:152-158. Cerca con Google

[128] Takahashi Y. EpitoPF of autoantibodies to N-methil-D-aspartate receptor heteromers in paraneoplastic limbic encephalitis. Ann Neurol 2008; 64: 110-111. Cerca con Google

[129] Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Sillewis Smitt P, Vedeler Ch, Verschuren JJGM, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neuropurg Psychiatry 2004; 75;1135-1140. Cerca con Google

[130] Dalamu J, Rosenfeld MR. Caracterization of neuronal antigens and antineuronal antibodies. In Phillips MI, Evans D (Eds). Methods in neuroscience. Neuroimmunology (vol 24). San Diego: Academic Press; 1995. p 216-71. Cerca con Google

[131] Alamowitch S, Graus F, Uchuya M, Renè R, Bescansa E and Delattre JY. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120: 923-928. Cerca con Google

[132] Messori A, Lanza C, Serio A, Savolini U. Resolution of limbic encephalitis with detection and treatment of lung cancer: clinical-radiological correlation. Eur J Radiol 2003; 45: 78-80. Cerca con Google

[133] Royas-Marcos I, Rousseau A, Keime-Guibert F, Renè R, Cartalat-Carel S, Delattre JY, Graus F. Specctrum of paraneoplastic neurologic disorders in womed with brest and gynecologic cancer. Medicine 2003; 82:216-223. Cerca con Google

[134] Mori O, Yamazaki M, Yamazaki M, KoiyamaT, Ohaki Y, Katayama Y, Naito Z. A presenile case of limbic encephalitis and cerebellar degeneration with subacute onset of progressive dementia. J Nippon Med Sch 2004; 71 (6): 412-416. Cerca con Google

[135] Moll JWB, Vecht CH. Paraneoplastic syndrome of the central nervous system. In Ch.J. Vecht (Ed) Handbook of Clinical Neurology, Vol 25(69) Neuro-Oncology part III. Elsevier Science 1997 p 349-365. Cerca con Google

[136] Sutton I, Winer J, Rowlands D, Dalmau J. Limbic encephalitis and antibodies to Ma2: a paraneoplastic presentation of breast cancer. J Neurol Neurosurg Psychiatry 200; 69:266-268. Cerca con Google

[137] Bien CG, Ubrach H, Schramm J, Soeder BM, Becker AJ, Voltz R, Vincent A, Elger CE. Limbic encephalitis as a precipitanting event in adult-onset temporal lobe epilepsy. Neurology 2007;69: 1236-1244. Cerca con Google

[138] Kerling F, Blumcke I, Stefan H. Pitfalls in diagnosing limbic encephalitis- a case report. Acta Neurol Scand 2008: 1-4. Cerca con Google

[139] Harloff A, Hummer S, Kleinschidt M, Rauer S. Anti-Ri antibodies and limbic encephalitis in a patient with carcinoid tumor of the lung. J Neurol 2005; 252:1404-1405. Cerca con Google

[140] Launary M, Bozzolo E, Vennisacc N, Delemont E, Fredenrich A, Thomas P. Paraneoplastic limbic encephalitis with positive anti-Ri antibodies and mediastinal seminoma. Rev Neurol (Paris). 2008: 164:612-619. Cerca con Google

[141] Cross SA, Saolma DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5 IgG. Ann Neurol 2003; 54: 38-50. Cerca con Google

[142] Antoine JC, Honnorta J, Anterion CT, Aguera M, Absi L, Fornel P, Michel D. Limbic encephalitis and immunologica Perturbation in two patients with thymoma. J Neurol Neurosurg Psychiarty 1995;58: 706-710. Cerca con Google

[143] Honnorat JC, Antoine JC, Derrington E, Auera M, Belin MF. Antibodies to a subpopultion of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996; 61: 270-278. Cerca con Google

[144] Bernal F, Shams’ili S, Rojas I, Sanchez-Valle R, Saz A, Dalau J, Honnorat J, Sillevis Smitt, Graus F. Anti-Tr antibodies as a markers of paraneoplastic cerebellar degeneration and Hodkin’disease. Neurology 2003; 60:230-234. Cerca con Google

[145] Kung S, Mueller PS, Geda YE, Krahan LE. Delirium resulting from paraneoplastic limbic encephalitis caused by Hodkin’s disease. Psychosomatics 2002; 43: 498-501. Cerca con Google

[146] Bernard P, Vinzio S, Talarmin F, Kadouri A, Flocard F. Hodgkin’s disease manifesting as paraneoplastic limbic encephalitis. Rev Med Interne 2003; 24: 257-260. Cerca con Google

[147] Epaulard O, Courby S, Pavese P, Grand S, Laramas M, Molina L, Brion JP, Colle PF. Sotto JJ. Paraneoplastic acute diffuse encephalitis revealing Hogkin’s disease. Leuk and Lymph 2004; 45:2509-2512. Cerca con Google

[148] Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry 2007; 78:381-385. Cerca con Google

[149] Maddison P, Lang B. Paraneoplastic neurological autoimmunity and survival in small sell lung cancer. J Neuroimmunol 2008; 159-162. Cerca con Google

[150] SherPerd JD, Huganir RL. The cell biology of synaptic plasticity: AMPA receptor trafficking. Ann Rev Cell Dev Biol. 2007; 23:613-643. Cerca con Google

[151] Sprengel R. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res 2006; 326:447-445. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record